Sickle Cell Disease - Stroke Prevention in Nigeria Trial

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 24, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Sickle Cell AnemiaSickle Cell DiseaseStroke
Interventions
DRUG

Hydroxyurea

Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)

Trial Locations (1)

P.MB. 3452

Aminu Kano Teaching Hospital, Kano

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Aminu Kano Teaching Hospital

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT01801423 - Sickle Cell Disease - Stroke Prevention in Nigeria Trial | Biotech Hunter | Biotech Hunter